Provider Letter OHCA 2017-04 Prior Authorization of Medications Used to Treat Skin Cancer

Effective April 10, 2017, the Oklahoma Health Care Authority (OHCA) will require a prior authorization (PA) for the following medications: Odomzo® (Sonidegib), Erivedge® (Vismodegib), Keytruda® (Pembrolizumab), Opdivo® (Nivolumab), Yervoy® (Ipilimumab), Tafinlar® (Dabrafenib), Zelboraf® (Vemurafenib), Cotellic® (Cobimetinib), Mekinist® (Trametinib), Imlygic® (Talimogene Laherparepvec).

If a SoonerCare member is currently on therapy with one of these medications, the medication will be “grandfathered.” Based on past claims, PA will be automatic for drugs obtained through the pharmacy claim system.

Please view the Provider Letter in its entirety here: Provider Letter 2017-04.

Submit all comments by close of business, April 10, 2017, via the comment box below.




Name (optional)

Email (optional)



Please note that all comments must be reviewed and approved prior to posting. Approved comments will be posted Monday through Friday between the hours of 7:30 a.m. – 4 p.m. Any comments received after 4 p.m. will be posted on the following business day.